Sun Pharma Q3 Results Review - Specialty Sales Remains Encouraging: Motilal Oswal

Performance was inline, despite regulatory hurdle at Halol, step-up in other expenses, due to higher selling, distribution spent.

Motilal Oswal Financial Services

01 Feb 2023, 10:13 AM IST

A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai. (Photo: Francis Mascarenhas/Reuters)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Sun Pharma Q3 Results Review - Specialty Sales Remains Encouraging: Motilal Oswal

Performance was inline, despite regulatory hurdle at Halol, step-up in other expenses, due to higher selling, distribution spent.

Choose a plan